Hepatitis Therapeutics Market Report 2026

Hepatitis Therapeutics Market Overview

• Hepatitis Therapeutics market size has reached to $19.08 billion in 2025 • Expected to grow to $23.43 billion in 2030 at a compound annual growth rate (CAGR) of 4.3% • Growth Driver: The Role Of Increasing Clinical Trials In Driving Growth Of The Hepatitis Therapeutic Market • Market Trend: Strategic Collaborations In The Fight Against Hepatitis • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Hepatitis Therapeutics Market?

Hepatitis is an inflammation of the liver caused by several viruses and non-viruses. The term hepatitis therapeutics describes the drugs that are used to treat all forms of hepatitis. The two drugs used to treat hepatitis are immune modulators and oral antivirals. The main disease types treated using hepatitis therapeutics includes hepatitis A, hepatitis B, hepatitis C and other disease types. Hepatitis A refers to liver inflammation that can result in mild to severe sickness. They are classified based on drug class into oral antivirals and immune modulators and are distributed using hospital pharmacies, drug stores and retail pharmacies and online providers.

What Is The Hepatitis Therapeutics Market Growth Forecast?

The hepatitis therapeutics market size is expected to see steady growth in the next few years. It will grow to $23.43 billion in 2030 at a compound annual growth rate (CAGR) of 4.3%. The growth in the forecast period can be attributed to growing uptake of direct-acting antivirals, rising investment in novel immune modulators, improved access to treatment in emerging markets, increasing diagnosis rates through screening programs, pipeline development for pan-genotypic therapies. Major trends in the forecast period include rising adoption of direct-acting antivirals for hepatitis c, increasing focus on combination therapies for chronic hepatitis, expansion of vaccination programs for hepatitis prevention, shift toward oral antiviral-based long-term management, growing use of online and specialty pharmacies for drug access.

Global Hepatitis Therapeutics Market Segmentation

1) By Disease Type: Hepatitis A, Hepatitis B, Hepatitis C, Other Disease Types 2) By Drug Class: Oral Antivirals, Immune Modulators 3) By Distribution Channel: Hospital Pharmacies, Drug Stores And Retail Pharmacies, Online Providers Subsegments: 1) By Hepatitis A: Vaccines, Post-Exposure Prophylaxis (PEP) 2) By Hepatitis B: Antiviral Medications, Immune Modulators, Vaccines 3) By Hepatitis C: Direct-Acting Antivirals (DAAs), Ribavirin, Interferon-Based Therapies 4) By Other Disease Types: Hepatitis D, Hepatitis E

What Is The Driver Of The Hepatitis Therapeutics Market?

The growing number of clinical trials is expected to propel the growth of the hepatitis therapeutic market going forward. Clinical trials are research studies that evaluate new treatments, medications, or interventions in human participants. Clinical trials play a crucial role in the development of new hepatitis therapeutics by providing a rigorous and ethical framework for evaluating the safety and efficacy of potential treatments, ensuring that patients have access to the most effective and beneficial therapies available. For instance, in December 2024, according to the Association of the British Pharmaceutical Industry, a UK-based nonprofit organization, the number of industry-initiated clinical trials in the UK grew from 411 trials in 2022 to 426 trials in 2023, marking a 3.7% increase. Therefore, the growing number of clinical trials is driving the growth of the hepatitis therapeutics industry.

Key Players In The Global Hepatitis Therapeutics Market

Major companies operating in the hepatitis therapeutics market are Gilead Sciences Inc., Bristol-Myers Squibb Co., AbbVie Inc., Merck & Co. Inc., Johnson & Johnson Services Inc., Cipla Inc., F Hoffmann-La Roche Ltd., Biocon Limited, LAURUS Labs Ltd., Zydus Lifesciences Limited, Hetero Healthcare Limited, Novartis AG, Sanofi SA, GlaxoSmithKline plc, Lupin Ltd., Teva Pharmaceutical Industries Ltd., NATCO Pharma Limited, Pfizer Inc., AstraZeneca plc, Boehringer Ingelheim International GmbH, Biocon Biopharmaceuticals Pvt. Ltd.

Global Hepatitis Therapeutics Market Trends and Insights

Major companies operating in the hepatitis therapeutics market are focusing on agreements to develop therapeutics to gain a competitive edge in the market. A strategic agreement is a formal contract between two or more parties that outlines the terms of their cooperation in achieving shared business goals. For instance, in October 2023, GlaxoSmithKline PLC, a UK-based pharmaceutical and biotechnology company, announced an agreement to obtain an exclusive license for JNJ-3989. It is an investigational subcutaneous RNA interference (RNAi) therapeutic for the treatment of chronic hepatitis B (CHB). JNJ-3989 is a novel RNAi therapeutic that targets the hepatitis B virus (HBV) X protein. The X protein is essential for HBV replication and viral persistence.

What Are Latest Mergers And Acquisitions In The Hepatitis Therapeutics Market?

In February 2024, Gilead Sciences Inc., a US-based pharmaceutical company, acquired Cymabay Therapeutics, Inc., for an undisclosed amount. Through this acquisition, Gilead aims to enhance its liver disease portfolio by integrating seladelpar, an investigational treatment for primary biliary cholangitis (PBC), to address unmet medical needs and improve treatment options for patients with chronic liver conditions. Cymabay Therapeutics, Inc., is a US-based clinical-stage biopharmaceutical company focused on developing innovative therapies for chronic diseases, particularly liver diseases and diabetes.

Regional Insights

North America was the largest region in the hepatitis therapeutics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the hepatitis therapeutics market report during the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Hepatitis Therapeutics Market?

The hepatitis therapeutics market consists of revenues earned by entities by providing services such as lifestyle modifications, nutritional support, and liver transplantation. The market value includes the value of related goods sold by the service provider or included within the service offering. The hepatitis therapeutics market also includes sales of corticosteroids, immune globulins, and Immune globulins which are used in providing hepatitis therapeutics services. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Hepatitis Therapeutics Market Report 2026?

The hepatitis therapeutics market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the hepatitis therapeutics industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.